Open/Close Menu

Julie HENRIQUES

Julie HENRIQUES  is a research engineer in biostatistics. She passed in 2010 a master’s degree in statistical modeling at the University of Franche-Comté. During the master’s degree’s internship in the biostatistics service of the Hospices Civils of Lyon, she realized a  study on the correction of survival estimates in the context of loss to follow-up in HIV cohort .  She worked as independent statistician for 5 years and participated to projects in many area such as financial times series, reservoir computing or EEG signal processing.
 
In 2015, she joined the Methodology and quality of life unit in Oncology (UMQVC) at the University hospital of Besancon.



Derniers articles

sample

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study"

AbstractIntroduction: Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Clinical colorectal cancer

sample

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

AbstractPurpose: The aim of this study was to investigate the association between expression of insulin-like growth...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Cell Oncol (Dordr)

sample

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

AbstractBackground: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : Cancer Imaging

sample

Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

AbstractBackground: Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Oncologist

sample

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

AbstractBackground: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced...

Posté par : Dr. Sophie PAGET-BAILLY, Mme. Julie HENRIQUES
Nom de la revue : Lancet

sample

Peritoneal dialysis after kidney transplant failure: a nationwide matched cohort study from the French Language Peritoneal Dialysis Registry (RDPLF)

AbstractBackground: Failed kidney transplant is becoming a frequent cause of dialysis initiation. Although studies...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : Nephrol Dial Transplant

01 February, 2020

Absorbable Polyglactin vs. Non-Cross-linked Porcine Biological Mesh for the Surgical Treatment of Infected Incisional Hernia

AbstractBackground: The use of absorbable meshes during contaminated or infected incisional hernia (IH) repair is...

Posté par : Mme. Julie HENRIQUES
Nom de la revue : J Gastrointest Surg

sample

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer

AbstractObjective: To evaluate the effects of switching from prednisone (P) to dexamethasone (D) at asymptomatic...

Posté par : Mme. Julie HENRIQUES, Pr. Franck BONNETAIN
Nom de la revue : BJU Int

sample

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study

AbstractHigh-risk HPV (hrHPV) testing has been implemented as a primary screening tool for cervical cancer in numerous...

Posté par : Dr. Sophie PAGET-BAILLY, Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Mme. Julie HENRIQUES
Nom de la revue : Cancers (Basel)

sample

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study

AbstractBackground: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for...

Posté par : Mme. Julie HENRIQUES, Dr. Dewi VERNEREY
Nom de la revue : JNCI Cancer Spectr.

2015-2024 © Copyright - UMQVC.org

↑

Website by Pearlweb